Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Theravance Biopharma (TBPH) Financials

Theravance Biopharma logo
$16.37 +0.03 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$16.38 +0.01 (+0.06%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Theravance Biopharma

Annual Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -182 -191 -285 -216 -236 -278 -199 872 -55 -56 106
Consolidated Net Income / (Loss)		 -182 -191 -285 -216 -236 -278 -199 872 -55 -56 106
Net Income / (Loss) Continuing Operations		 -182 -191 -285 -216 -236 -295 -265 -93 -55 -56 106
Total Pre-Tax Income 		-181 -181 -272 -226 -242 -303 -265 -93 -49 -45 129
Total Operating Income		 -182 -180 -260 -239 -252 -298 -258 -92 -56 -47 -3.60
Total Gross Profit		 37 46 9.36 60 73 72 55 51 57 64 107
Total Revenue		 42 49 15 60 73 72 55 51 57 64 107
Operating Revenue		 42 49 15 60 73 72 55 51 57 64 107
Total Cost of Revenue		 4.66 2.89 6.03 0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 219 226 269 298 325 369 313 143 113 111 111
Selling, General & Admin Expense		 90 85 96 97 106 109 99 67 70 69 74
Research & Development Expense		 129 142 174 201 219 261 194 63 41 38 37
Impairment Charge		 - - - - - - - - 0.00 4.51 0.00
Total Other Income / (Expense), net		 0.63 -0.09 -12 13 10 -5.72 -7.44 -0.86 6.77 2.34 133
Interest Expense		 0.00 1.40 8.55 10 32 8.55 8.55 9.40 2.35 2.55 2.46
Interest & Investment Income		 0.00 - -7.83 11 34 - - - - 0.00 50
Other Income / (Expense), net		 0.63 1.31 4.79 12 8.40 2.83 1.11 8.55 9.12 4.88 85
Income Tax Expense		 0.95 10 14 -11 -5.22 -8.52 -0.15 0.01 5.92 12 23
Basic Earnings per Share		 ($5.34) ($4.26) ($5.45) ($3.99) ($4.25) ($4.46) ($2.87) $11.85 ($1.00) ($1.15) $2.10
Weighted Average Basic Shares Outstanding		 34.15M 44.71M 52.35M 53.97M 55.61M 62.35M 69.46M 73.59M 55.30M 48.85M 50.32M
Diluted Earnings per Share		 ($5.34) ($4.26) ($5.45) ($3.99) ($4.25) ($4.46) ($2.87) $11.85 ($1.00) ($1.15) $2.06
Weighted Average Diluted Shares Outstanding		 34.15M 44.71M 52.35M 53.97M 55.61M 62.35M 69.46M 73.59M 55.30M 48.85M 51.51M
Weighted Average Basic & Diluted Shares Outstanding		 34.15M 44.71M 52.35M 53.97M 55.61M 62.35M 74.70M 62.86M 48.16M 49.47M 51.49M

Quarterly Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.95 -8.51 -12 -17 -13 -16 -14 55 3.62 61 -4.93
Consolidated Net Income / (Loss)		 -8.95 -8.51 -12 -17 -13 -16 -14 55 3.62 61 -4.93
Net Income / (Loss) Continuing Operations		 -8.95 -8.51 -12 -17 -13 -16 -14 55 3.62 61 -4.93
Total Pre-Tax Income 		-7.58 -5.02 -10 -15 -10 -8.94 -14 73 -2.89 73 -6.47
Total Operating Income		 -8.76 -6.24 -11 -16 -11 -9.20 -14 -2.73 -6.46 20 -9.48
Total Gross Profit		 16 18 15 14 17 19 15 26 20 46 18
Total Revenue		 16 18 15 14 17 19 15 26 20 46 18
Operating Revenue		 16 18 15 14 17 19 15 26 20 46 18
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 24 24 26 30 28 28 30 29 26 26 27
Selling, General & Admin Expense		 16 15 17 17 17 19 18 18 18 19 18
Research & Development Expense		 8.31 8.31 8.97 9.95 9.27 9.45 11 10 8.11 7.36 5.83
Restructuring Charge		 0.00 - - - - - 0.00 - - - 3.63
Total Other Income / (Expense), net		 1.18 1.22 0.81 0.48 0.79 0.26 0.30 76 3.57 53 3.01
Interest Expense		 0.61 0.62 0.63 0.64 0.63 0.64 0.64 0.66 0.57 0.58 0.00
Other Income / (Expense), net		 1.79 1.85 1.43 1.13 1.42 0.90 0.94 77 4.14 3.64 3.01
Income Tax Expense		 1.37 3.49 1.26 1.31 2.65 6.59 -0.56 18 -6.50 12 -1.54
Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31) ($0.27) $1.09 $0.07 $1.21 ($0.10)
Weighted Average Basic Shares Outstanding		 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M 49.71M 50.18M 50.52M 50.32M 51.28M
Diluted Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31) ($0.27) $1.08 $0.07 $1.18 ($0.10)
Weighted Average Diluted Shares Outstanding		 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M 49.71M 50.73M 51.91M 51.51M 51.28M
Weighted Average Basic & Diluted Shares Outstanding		 49.80M 48.16M 48.63M 48.92M 49.17M 49.47M 50.00M 50.36M 50.67M 51.49M 51.55M

Annual Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 23 232 -256 289 -320 23 8.50 208 -259 -1.75 130
Net Cash From Operating Activities		 -169 -99 -201 -113 -238 -250 -208 -187 -27 -12 239
Net Cash From Continuing Operating Activities		 -169 -99 -201 -113 -238 -263 -236 -2.43 -27 -12 239
Net Income / (Loss) Continuing Operations		 -182 -191 -285 -216 -236 -295 -265 -93 -55 -56 106
Consolidated Net Income / (Loss)		 -182 -191 -285 -216 -236 -278 -199 872 -55 -56 106
Depreciation Expense		 2.99 3.12 3.80 4.48 6.44 4.71 4.80 3.72 2.00 1.71 1.63
Amortization Expense		 - - - 0.00 -0.23 3.34 3.79 3.99 2.26 1.91 1.19
Non-Cash Adjustments To Reconcile Net Income		 15 68 60 34 23 50 70 42 25 29 131
Changes in Operating Assets and Liabilities, net		 -4.39 21 20 65 -31 -26 -50 41 -0.60 12 -1.07
Net Cash From Investing Activities		 111 -148 -56 177 -83 11 124 1,154 -33 12 -105
Net Cash From Continuing Investing Activities		 111 -148 -56 177 -83 11 124 59 -33 12 -105
Purchase of Property, Plant & Equipment		 -2.65 -2.14 -2.41 -7.24 -3.18 -6.62 -3.41 -0.57 -2.49 -0.33 -0.04
Purchase of Investments		 -73 -238 -289 -183 -424 -402 -158 -103 -135 -141 -248
Sale and/or Maturity of Investments		 187 91 235 347 339 419 286 158 103 156 143
Other Investing Activities, net		 - - - - - - - - 0.00 -2.29 0.00
Net Cash From Financing Activities		 81 479 1.66 225 1.29 263 92 -759 -199 -2.50 -3.25
Net Cash From Continuing Financing Activities		 81 479 1.66 225 1.29 280 92 -739 -199 -2.50 -3.25
Repurchase of Common Equity		 - - - - - 0.00 0.00 -129 -197 -0.45 0.00
Issuance of Common Equity		 82 256 3.98 4.17 3.47 144 112 0.80 0.62 0.61 0.02
Other Financing Activities, net		 -0.83 0.53 -2.32 -8.41 -0.03 -8.39 -9.06 21 -2.50 -2.66 -3.27
Cash Income Taxes Paid		 13 -9.49 4.93 -7.32 0.02 0.01 -4.09 118 0.02 0.11 28

Quarterly Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -34 -32 14 -7.49 -23 14 73 171 -107 -6.97 120
Net Cash From Operating Activities		 -2.49 -0.85 -1.02 -4.42 -5.20 -0.90 43 208 -6.51 -6.06 73
Net Cash From Continuing Operating Activities		 -2.49 -0.85 -1.02 -5.44 -5.20 -0.90 43 208 -6.51 -6.06 73
Net Income / (Loss) Continuing Operations		 -8.95 -8.51 -12 -17 -13 -16 -14 55 3.62 61 -4.93
Consolidated Net Income / (Loss)		 -8.95 -8.51 -12 -17 -13 -16 -14 55 3.62 61 -4.93
Depreciation Expense		 0.43 0.39 0.43 0.43 0.43 0.42 0.41 0.41 0.41 0.40 0.38
Amortization Expense		 0.51 1.03 0.75 0.55 0.33 0.27 0.64 0.52 0.23 -0.20 0.45
Non-Cash Adjustments To Reconcile Net Income		 3.60 3.81 7.19 7.20 4.73 10 57 141 -132 65 83
Changes in Operating Assets and Liabilities, net		 1.93 2.43 2.28 3.94 2.01 3.60 -1.37 11 121 -132 -5.24
Net Cash From Investing Activities		 -0.02 -0.68 17 -3.03 -17 16 31 -36 -100 0.59 53
Net Cash From Continuing Investing Activities		 -0.02 -0.68 17 14 -17 16 31 -36 -100 0.59 53
Purchase of Investments		 - - -27 -31 -45 -38 -1.97 -57 -125 -65 -43
Sale and/or Maturity of Investments		 - - 44 28 27 56 33 20 25 66 96
Net Cash From Financing Activities		 -31 -31 -1.72 -0.04 -0.37 -0.37 -0.85 -0.50 -0.40 -1.49 -5.58
Net Cash From Continuing Financing Activities		 -31 -31 -1.72 -1.76 -0.37 -0.37 -0.85 -0.50 -0.40 -1.49 -5.58
Issuance of Common Equity		 -0.00 0.17 0.00 - 0.03 0.16 0.02 - - - 0.00
Other Financing Activities, net		 -0.51 -0.52 -1.27 -0.46 -0.40 -0.53 -0.87 -0.50 -0.40 -1.49 -5.58
Cash Income Taxes Paid		 - 0.01 -0.01 0.02 - 0.10 0.00 8.90 13 6.21 -0.35

Annual Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 300 639 441 560 409 469 375 607 382 354 486
Total Current Assets		 237 529 379 533 338 393 250 353 134 161 418
Cash & Equivalents		 113 345 89 378 58 81 90 298 40 38 168
Short-Term Investments		 60 156 260 127 223 211 84 29 63 51 148
Prepaid Expenses		 5.12 2.41 3.70 11 7.09 31 19 9.20 14 4.28 7.56
Other Current Assets		 35 9.08 7.11 10 22 16 58 17 17 68 96
Plant, Property, & Equipment, net		 9.87 8.46 10 13 13 16 14 12 9.07 7.42 5.90
Total Noncurrent Assets		 53 102 52 14 58 59 111 242 239 186 61
Long-Term Investments		 51 100 42 12 4.99 13 - - - 0.00 11
Other Noncurrent Operating Assets		 1.08 1.89 1.88 2.37 49 47 111 242 239 186 50
Total Liabilities & Shareholders' Equity		 300 639 441 560 409 469 375 607 382 354 486
Total Liabilities		 57 289 326 612 633 773 713 166 169 179 189
Total Current Liabilities		 49 49 63 99 112 124 59 29 25 32 38
Accounts Payable		 19 1.73 5.92 9.03 4.76 6.78 3.10 1.55 1.52 2.24 2.57
Accrued Expenses		 20 33 32 19 24 37 24 10 6.39 6.26 6.91
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - 0.00 5.85 5.29
Current Employee Benefit Liabilities		 11 14 24 24 28 35 13 10 6.44 7.02 13
Other Current Liabilities		 - - - - 7.76 9.87 0.50 6.75 10 11 11
Total Noncurrent Liabilities		 7.58 240 264 513 521 649 655 137 144 147 151
Other Noncurrent Operating Liabilities		 2.98 13 35 254 288 422 426 73 79 147 151
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 243 350 115 -52 -224 -304 -339 442 213 176 297
Total Preferred & Common Equity		 243 350 115 -52 -224 -304 -339 442 213 176 297
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 243 350 115 -52 -224 -304 -339 442 213 176 297
Common Stock		 565 863 914 961 1,025 1,223 1,387 1,296 1,122 1,141 1,156
Retained Earnings		 -322 -512 -798 -1,012 -1,249 -1,527 -1,726 -854 -909 -966 -860
Accumulated Other Comprehensive Income / (Loss)		 -0.07 -0.25 -0.73 -0.17 0.15 0.05 0.00 -0.02 -0.07 0.01 0.06

Quarterly Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 763 539 447 414 371 362 356 344 426 415 472
Total Current Assets		 512 261 192 162 124 119 116 150 366 355 418
Cash & Equivalents		 419 188 106 72 54 46 23 111 282 175 288
Short-Term Investments		 68 54 62 62 46 50 68 20 57 155 107
Prepaid Expenses		 11 7.81 8.76 11 9.66 8.93 8.27 4.06 5.57 6.75 7.38
Other Current Assets		 14 12 16 17 15 14 17 15 22 18 16
Plant, Property, & Equipment, net		 12 12 9.55 9.29 8.72 8.14 7.79 7.03 6.64 6.26 5.54
Total Noncurrent Assets		 240 265 245 243 238 235 232 186 53 55 49
Long-Term Investments		 - 19 - - - - - - - 3.03 0.00
Other Noncurrent Operating Assets		 240 246 245 243 238 235 232 186 53 51 49
Total Liabilities & Shareholders' Equity		 763 539 447 414 371 362 356 344 426 415 472
Total Liabilities		 283 168 166 167 166 168 170 178 201 183 182
Total Current Liabilities		 142 26 25 25 22 23 23 32 55 37 32
Accounts Payable		 5.34 2.66 1.57 2.37 1.69 1.67 1.45 2.41 1.68 2.21 1.10
Accrued Expenses		 7.97 11 8.42 6.69 4.95 4.79 3.45 7.05 8.11 9.88 5.91
Current Deferred & Payable Income Tax Liabilities		 121 - - - - - - 5.85 27 4.07 5.29
Current Employee Benefit Liabilities		 7.56 5.03 5.37 6.58 4.48 5.77 7.84 5.39 7.26 10 8.73
Other Current Liabilities		 0.69 7.43 9.16 9.71 11 11 11 11 11 11 11
Total Noncurrent Liabilities		 141 142 142 142 145 145 147 146 147 145 150
Other Noncurrent Operating Liabilities		 78 77 77 76 78 76 75 70 69 66 150
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 481 371 280 246 205 194 186 166 225 233 291
Total Preferred & Common Equity		 481 371 280 246 205 194 186 166 225 233 291
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 481 371 280 246 205 194 186 166 225 233 291
Common Stock		 1,324 1,247 1,172 1,147 1,126 1,131 1,136 1,145 1,149 1,153 1,155
Retained Earnings		 -844 -876 -892 -901 -921 -937 -950 -979 -924 -921 -865
Accumulated Other Comprehensive Income / (Loss)		 -0.12 0.05 -0.29 -0.23 -0.04 -0.02 0.05 0.00 -0.01 0.03 -0.06

Annual Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 37,839,185.00 51,942,489.00 54,103,378.00 55,411,264.00 56,762,307.00 63,981,317.00 73,698,388.00 - - - 50,672,431.00
DEI Adjusted Shares Outstanding		 37,839,185.00 51,942,489.00 54,103,378.00 55,411,264.00 56,762,307.00 63,981,317.00 73,698,388.00 - - - 50,672,431.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.82 -3.67 -5.28 -3.89 -4.17 -4.35 -2.71 - - - 2.09
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -127 -126 -182 -167 -176 -208 -180 -64 -39 -33 -2.95
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -18.42% -18.72% -0.99%
Earnings before Interest and Taxes (EBIT)		 -181 -179 -255 -227 -244 -295 -257 -83 -47 -42 82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -178 -176 -252 -222 -237 -287 -248 -76 -43 -38 85
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -163 -79 -159 122 -249 -117 -274 -445 -35 -9.49 114
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 19 -29 -52 -341 -268 -359 -266 114 111 87 -30
Increase / (Decrease) in Invested Capital		 36 -48 -23 -289 73 -91 93 380 -3.75 -23 -117
Book Value per Share		 $6.42 $6.74 $2.13 ($0.93) ($3.94) ($4.75) ($4.59) $6.56 $4.28 $3.57 $5.86
Tangible Book Value per Share		 $6.42 $6.74 $2.13 ($0.93) ($3.94) ($4.75) ($4.59) $6.56 $4.28 $3.57 $5.86
Total Capital		 243 573 339 173 12 -57 -94 442 213 176 297
Total Debt		 0.00 223 224 225 236 246 245 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 223 224 225 226 227 228 0.00 0.00 0.00 0.00
Net Debt		 -223 -378 -166 -292 -50 -59 72 -327 -102 -88 -326
Capital Expenditures (CapEx)		 2.65 2.14 2.41 7.22 3.17 6.55 3.40 -1.29 0.98 0.33 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 16 -22 -32 -71 -44 -3.84 35 -2.74 6.35 41 65
Debt-free Net Working Capital (DFNWC)		 188 479 316 434 237 289 208 325 109 129 380
Net Working Capital (NWC)		 188 479 316 434 227 270 191 325 109 129 380
Net Nonoperating Expense (NNE)		 55 64 103 48 60 70 19 -937 16 24 -109
Net Nonoperating Obligations (NNO)		 -224 -379 -167 -289 -44 -55 73 -327 -102 -88 -326
Total Depreciation and Amortization (D&A)		 2.99 3.12 3.80 4.48 6.21 8.05 8.59 7.71 4.26 3.62 2.81
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.34) ($4.26) ($5.45) ($3.99) ($4.25) ($4.46) ($2.87) $11.85 ($1.00) ($1.15) $2.10
Adjusted Weighted Average Basic Shares Outstanding		 38.43M 52.86M 54.38M 55.58M 62.52M 64.33M 69.46M 73.59M 55.30M 48.85M 50.32M
Adjusted Diluted Earnings per Share		 ($5.34) ($4.26) ($5.45) ($3.99) ($4.25) ($4.46) ($2.87) $11.85 ($1.00) ($1.15) $2.06
Adjusted Weighted Average Diluted Shares Outstanding		 38.43M 52.86M 54.38M 55.58M 62.52M 64.33M 69.46M 73.59M 55.30M 48.85M 51.51M
Adjusted Basic & Diluted Earnings per Share		 ($5.34) ($4.26) ($5.45) ($3.99) ($4.25) ($4.46) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 34.15M 44.71M 52.35M 53.97M 55.61M 62.35M 74.70M 62.86M 48.16M 49.47M 51.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -127 -126 -182 -167 -176 -208 -166 -55 -37 -30 -2.95
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 49,470,647.00 50,001,332.00 50,361,296.00 50,672,431.00 51,492,924.00
DEI Adjusted Shares Outstanding		 - - - - - - 49,470,647.00 50,001,332.00 50,361,296.00 50,672,431.00 51,492,924.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.27 1.10 0.07 1.20 -0.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 26.04% 19.91% 39.22% 3.69% 7.49% 6.77% 6.10% 83.75% 18.51% - 15.02%
EBITDA Growth		 35.54% 73.77% 58.99% -7.11% -43.45% -155.41% -44.79% 650.05% 80.60% - 54.71%
EBIT Growth		 39.06% 67.96% 55.44% -7.03% -35.10% -88.85% -38.08% 606.75% 75.42% - 52.06%
NOPAT Growth		 38.32% 64.20% 55.01% 2.59% -23.71% -47.44% -28.79% 81.43% 40.44% - 34.30%
Net Income Growth		 -100.98% 17.87% 47.19% -5.65% -41.88% -82.46% -16.42% 431.75% 128.47% - 63.67%
EPS Growth		 -101.40% -225.00% 31.43% -21.43% -52.94% -55.00% -12.50% 417.65% 126.92% - 62.96%
Operating Cash Flow Growth		 88.77% 99.31% 90.89% 64.50% -109.01% -5.62% 4,311.25% 4,812.89% -25.25% - 70.26%
Free Cash Flow Firm Growth		 63.64% 99.84% 99.54% 100.79% 108.23% 2,826.89% 2,789.99% 5,003.54% 1,752.08% - 122.19%
Invested Capital Growth		 1,892.88% -3.28% -5.09% -13.40% -15.91% -21.14% -66.51% -216.75% -206.08% - -396.27%
Revenue Q/Q Growth		 14.14% 11.93% -17.43% -1.70% 18.32% 11.18% -17.95% 70.23% -23.69% - -61.43%
EBITDA Q/Q Growth		 52.45% 50.70% -234.01% -58.23% 36.31% 12.23% -63.70% 701.11% -102.25% - -123.63%
EBIT Q/Q Growth		 48.79% 37.01% -122.47% -49.16% 35.36% 11.95% -62.67% 647.38% -103.14% - -127.36%
NOPAT Q/Q Growth		 45.67% 28.77% -79.60% -40.14% 31.00% 15.11% -56.89% 79.80% -121.37% - -139.72%
Net Income Q/Q Growth		 42.79% 4.92% -37.06% -41.71% 23.18% -22.28% 12.55% 503.82% -93.41% - -108.08%
EPS Q/Q Growth		 39.29% -17.65% -20.00% -41.67% 23.53% -19.23% 12.90% 500.00% -93.52% - -108.47%
Operating Cash Flow Q/Q Growth		 80.01% 65.65% -19.67% -332.00% -17.69% 82.64% 4,871.51% 383.45% -103.13% - 1,308.43%
Free Cash Flow Firm Q/Q Growth		 76.16% 99.50% -257.15% 285.11% 149.62% 65.24% 252.32% 251.19% -9.41% - -0.83%
Invested Capital Q/Q Growth		 -0.52% -1.39% -5.13% -6.94% -3.40% -7.53% -59.71% -424.40% 12.22% - -249.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -38.47% -16.94% -59.26% -95.38% -51.34% -40.53% -80.86% 285.54% -8.40% - -31.84%
Operating Margin		 -55.82% -35.53% -77.27% -110.16% -64.25% -49.06% -93.80% -10.40% -32.29% - -53.58%
EBIT Margin		 -44.44% -25.01% -67.39% -102.25% -55.86% -44.24% -87.70% 282.00% -11.59% - -36.56%
Profit (Net Income) Margin		 -57.03% -48.45% -80.42% -115.94% -75.28% -82.79% -88.24% 209.33% 18.08% - -27.87%
Tax Burden Percent		 118.03% 169.66% 112.13% 108.59% 126.32% 173.70% 96.05% 74.91% -125.13% - 76.24%
Interest Burden Percent		 108.73% 114.18% 106.44% 104.42% 106.69% 107.75% 104.76% 99.10% 124.74% - 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.09% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 -40.23% -12.70% -30.89% -45.48% -27.53% -22.36% -61.21% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -39.33% -10.77% -28.77% -41.28% -23.00% -12.83% -58.20% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 33.60% 7.07% 18.00% 22.96% 12.00% 6.30% 36.23% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -6.64% -5.63% -12.89% -22.52% -15.53% -16.06% -24.99% 6.23% 14.03% - 50.17%
Cash Return on Invested Capital (CROIC)		 -147.55% -31.55% -22.29% -13.54% -12.56% -9.60% 49.48% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 -4.12% -2.90% -9.11% -15.68% -9.17% -7.74% -16.01% 55.25% -2.41% - -9.84%
Return on Assets (ROA)		 -5.28% -5.62% -10.87% -17.78% -12.36% -14.48% -16.11% 41.02% 3.77% - -7.50%
Return on Common Equity (ROCE)		 -6.64% -5.63% -12.89% -22.52% -15.53% -16.06% -24.99% 6.23% 14.03% - 50.17%
Return on Equity Simple (ROE_SIMPLE)		 -23.18% 0.00% -21.85% -23.57% -26.61% 0.00% -35.14% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.13 -4.37 -7.84 -11 -7.59 -6.44 -10 -2.04 -4.52 17 -6.64
NOPAT Margin		 -39.07% -24.87% -54.09% -77.11% -44.97% -34.34% -65.66% -7.79% -22.60% - -37.51%
Net Nonoperating Expense Percent (NNEP)		 -0.91% -1.93% -2.12% -4.20% -4.54% -9.53% -3.01% 26.16% 3.84% - 0.65%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.05% - - - -3.67% -6.09% -0.91% -1.94% 5.63% -2.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 102.86% 88.20% 115.44% 119.64% 100.04% 98.65% 119.38% 70.36% 91.71% - 100.12%
R&D to Revenue		 52.96% 47.33% 61.84% 69.82% 54.94% 50.41% 74.42% 40.05% 40.58% - 32.93%
Operating Expenses to Revenue		 155.82% 135.53% 177.27% 210.16% 164.25% 149.06% 193.80% 110.40% 132.29% - 153.58%
Earnings before Interest and Taxes (EBIT)		 -6.97 -4.39 -9.77 -15 -9.42 -8.30 -13 74 -2.32 24 -6.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.04 -2.98 -8.59 -14 -8.66 -7.60 -12 75 -1.68 24 -5.64
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.85 2.63 2.11 2.13 2.12 2.64 2.66 2.45 3.16 - 2.88
Price to Tangible Book Value (P/TBV)		 1.85 2.63 2.11 2.13 2.12 2.64 2.66 2.45 3.16 - 2.88
Price to Revenue (P/Rev)		 8.36 9.75 7.02 6.65 6.24 7.19 6.77 7.14 9.15 - 7.61
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 42.32 25.06 - 7.30
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.36% 3.99% - 13.71%
Enterprise Value to Invested Capital (EV/IC)		 2.87 4.14 3.17 3.24 3.21 4.29 8.85 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 5.90 7.96 5.40 5.10 4.79 5.82 4.76 2.76 5.01 - 4.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.61 7.59 - 4.83
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.99 8.09 - 4.97
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 390.82
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 9.56 0.87 1.65 - 1.64
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 8.98 1.07 2.31 - 3.14
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.85 -0.66 -0.63 -0.56 -0.52 -0.49 -0.62 -1.04 -1.01 - -1.15
Leverage Ratio		 1.62 1.51 1.58 1.71 1.78 1.89 1.93 1.88 1.84 - 1.79
Compound Leverage Factor		 1.76 1.73 1.68 1.78 1.90 2.04 2.02 1.87 2.30 - 1.79
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -0.94 -0.89 -1.50 -1.80 -1.94 -1.72 -2.02 0.24 0.40 - 1.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.37 5.39 5.74 5.20 4.97 5.02 4.77 6.70 9.48 - 13.14
Quick Ratio		 5.28 4.14 4.62 4.19 3.90 2.75 4.15 6.20 8.81 - 12.42
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -125 -0.62 -2.22 4.11 10 17 60 210 190 134 133
Operating Cash Flow to CapEx		 -11,838.10% -126.14% -1,123.08% -12,263.89% -34,640.00% -474.74% 0.00% 611,982.35% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 -204.45 -1.00 -3.53 6.38 16.27 26.34 92.79 316.03 331.24 - 0.00
Operating Cash Flow to Interest Expense		 -4.08 -1.37 -1.62 -6.86 -8.25 -1.40 66.93 313.84 -11.36 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.12 -2.46 -1.77 -6.91 -8.27 -1.70 66.93 313.79 -11.36 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.09 0.12 0.14 0.15 0.16 0.17 0.18 0.20 0.21 - 0.27
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 5.15 5.48 5.91 7.01 7.40 7.81 8.29 10.45 11.44 - 17.47
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 112 111 105 98 94 87 35 -114 -100 -30 -104
Invested Capital Turnover		 1.03 0.51 0.57 0.59 0.61 0.65 0.93 -9.45 -28.01 - -3.18
Increase / (Decrease) in Invested Capital		 118 -3.75 -5.63 -15 -18 -23 -70 -212 -194 -117 -139
Enterprise Value (EV)		 322 457 332 316 303 374 311 213 403 - 441
Market Capitalization		 456 560 432 412 394 463 442 552 735 - 836
Book Value per Share		 $4.66 $4.28 $4.25 $3.98 $3.79 $3.57 $3.36 $4.50 $4.62 $5.86 $5.64
Tangible Book Value per Share		 $4.66 $4.28 $4.25 $3.98 $3.79 $3.57 $3.36 $4.50 $4.62 $5.86 $5.64
Total Capital		 246 213 205 194 186 176 166 225 233 297 291
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -134 -102 -100 -96 -91 -88 -131 -339 -333 -326 -395
Capital Expenditures (CapEx)		 0.02 0.68 0.09 0.04 0.02 0.19 0.00 0.03 0.00 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.32 6.35 2.66 0.28 1.68 41 -12 -27 -12 65 -8.81
Debt-free Net Working Capital (DFNWC)		 136 109 103 96 93 129 119 312 317 380 386
Net Working Capital (NWC)		 136 109 103 96 93 129 119 312 317 380 386
Net Nonoperating Expense (NNE)		 2.82 4.14 3.82 5.54 5.11 9.09 3.48 -57 -8.13 -44 -1.71
Net Nonoperating Obligations (NNO)		 -134 -102 -100 -96 -91 -88 -131 -339 -333 -326 -395
Total Depreciation and Amortization (D&A)		 0.94 1.42 1.18 0.98 0.76 0.70 1.05 0.93 0.64 0.20 0.84
Debt-free, Cash-free Net Working Capital to Revenue		 4.25% 11.05% 4.32% 0.46% 2.66% 63.11% -18.53% -35.16% -15.42% - -8.02%
Debt-free Net Working Capital to Revenue		 250.10% 189.42% 166.85% 155.38% 147.24% 200.34% 181.97% 403.68% 395.00% - 351.50%
Net Working Capital to Revenue		 250.10% 189.42% 166.85% 155.38% 147.24% 200.34% 181.97% 403.68% 395.00% - 351.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31) ($0.27) $1.09 $0.07 $1.21 ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M 49.71M 50.18M 50.52M 50.32M 51.28M
Adjusted Diluted Earnings per Share		 ($0.17) ($0.20) ($0.24) ($0.34) ($0.26) ($0.31) ($0.27) $1.08 $0.07 $1.18 ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 52.36M 55.30M 48.28M 48.75M 49.04M 48.85M 49.71M 50.73M 51.91M 51.51M 51.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.80M 48.16M 48.63M 48.92M 49.17M 49.47M 50.00M 50.36M 50.67M 51.49M 51.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.13 -4.37 -7.84 -8.93 -6.49 -6.44 -10 -2.04 -4.52 17 -4.10
Normalized NOPAT Margin		 -39.07% -24.87% -54.09% -62.62% -38.49% -34.34% -65.66% -7.79% -22.60% - -23.14%
Pre Tax Income Margin		 -48.32% -28.56% -71.72% -106.77% -59.59% -47.66% -91.88% 279.47% -14.45% - -36.56%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -11.45 -7.05 -15.54 -22.64 -14.96 -12.90 -20.99 111.42 -4.04 - 0.00
NOPAT to Interest Expense		 -10.07 -7.01 -12.47 -17.07 -12.04 -10.02 -15.71 -3.08 -7.89 - 0.00
EBIT Less CapEx to Interest Expense		 -11.49 -8.14 -15.68 -22.69 -14.98 -13.20 -20.99 111.37 -4.04 - 0.00
NOPAT Less CapEx to Interest Expense		 -10.10 -8.10 -12.62 -17.13 -12.06 -10.31 -15.71 -3.13 -7.89 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -353.37% -357.02% -317.50% -134.93% -62.16% -0.79% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Theravance Biopharma (NASDAQ: TBPH) has shown a mix of profitability and volatility across the last four years of quarterly data. While several quarters delivered meaningful net income and strong operating cash flow, other periods featured losses and notable working-capital and investing-driven movements. Below are the key trends, grouped by likely impact on the stock.

  • Strong Q4 2025 profitability: Net income from continuing operations was $61.0 million with basic EPS of $1.21 and diluted EPS of $1.18, aided by notable non-operating income and investment gains in the quarter.
  • Solid Q2 2025 profitability: Net income from continuing operations of $54.8 million, with basic EPS about $1.09 and diluted EPS about $1.08, indicating a second strong quarter of earnings power.
  • Low or zero debt: Long-Term Debt is reported as 0 across recent balance sheets, reducing interest costs and financial risk.
  • Notable liquidity presence: Cash & equivalents were around $282 million in Q2 2025 and roughly $175 million in Q3 2025, signaling a healthy liquidity cushion for ongoing trials, partnerships, and operating needs.
  • One-time investment gains boost Q4 2025: Q4 2025 includes substantial other income (around $53.1 million) and a sale/maturity of investments (about $65.5 million), contributing to the quarterly net income non-operating uplift.
  • Modest and variable revenue base: Operating revenue stays in the low tens of millions per quarter (roughly $16–$46 million range across periods), suggesting limited top-line growth without major product launches or licensing deals.
  • Quarterly profitability volatility: Net income swings—from substantial profits in some quarters to losses in others (e.g., negative results in Q1 2025 and some 2024 periods)—reflect exposure to non-operating items and calendar-driven events rather than steady operating cash flow.
  • Deficits vs. equity balance: Retained earnings have shown negative levels at times, though total equity remained positive due to other equity components; this highlights ongoing deficits historically offset by equity contributions or gains.
  • Operating cash flow weakness in Q4 2025: Net cash from continuing operating activities was negative in Q4 2025 (-$6.1 million), driven by working-capital changes, signaling near-term operating cash-flow volatility.
  • Investing cash flow pressure in Q3 2025: Net cash from investing activities was heavily negative in Q3 2025 (about -$100.2 million), largely due to purchases of investments, which can strain near-term cash availability despite favorable net income in other periods.
05/22/26 09:32 PM ETAI Generated. May Contain Errors.

Theravance Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Theravance Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Theravance Biopharma's net income appears to be on a downward trend, with a most recent value of $105.90 million in 2025, falling from -$182.22 million in 2015. The previous period was -$56.42 million in 2024. Check out Theravance Biopharma's forecast to explore projected trends and price targets.

Theravance Biopharma's total operating income in 2025 was -$3.60 million, based on the following breakdown:
  • Total Gross Profit: $107.46 million
  • Total Operating Expenses: $111.07 million

Over the last 10 years, Theravance Biopharma's total revenue changed from $42.13 million in 2015 to $107.46 million in 2025, a change of 155.1%.

Theravance Biopharma's total liabilities were at $188.85 million at the end of 2025, a 5.7% increase from 2024, and a 231.0% increase since 2015.

In the past 10 years, Theravance Biopharma's cash and equivalents has ranged from $37.80 million in 2024 to $378.02 million in 2018, and is currently $167.81 million as of their latest financial filing in 2025.

Over the last 10 years, Theravance Biopharma's book value per share changed from 6.42 in 2015 to 5.86 in 2025, a change of -8.8%.


Related Companies

Financial statements for NASDAQ:TBPH last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
The Most Important Tech Company in America?
One private company holds over $26 billion in government contracts tied to AI warfare and defense systems - an...
Banyan Hill Publishing | Sponsoredtc pixel
Your computer is about to become a museum piece
Vanguard holds $101 billion in three AI companies most investors have never heard of. BlackRock holds $82 bill...
Eagle Publishing | Sponsoredtc pixel